The relation between prescribing of different antibiotics and rates of mortality with sepsis in US adults.


Journal

BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551

Informations de publication

Date de publication:
22 Feb 2020
Historique:
received: 02 08 2019
accepted: 18 02 2020
entrez: 24 2 2020
pubmed: 24 2 2020
medline: 6 5 2020
Statut: epublish

Résumé

Antibiotic use contributes to the rates of sepsis and the associated mortality, particularly through lack of clearance of resistant infections following antibiotic treatment. At the same time, there is limited information on the effects of prescribing of some antibiotics vs. others on subsequent sepsis and sepsis-related mortality. We used a multivariable mixed-effects model to relate state-specific rates of outpatient prescribing overall for oral fluoroquinolones, penicillins, macrolides, and cephalosporins between 2014 and 2015 to state-specific rates of mortality with sepsis (ICD-10 codes A40-41 present as either underlying or contributing causes of death on a death certificate) in different age groups of US adults between 2014 and 2015, adjusting for additional covariates and random effects associated with the ten US Health and Human Services (HHS) regions. Increase in the rate of prescribing of oral penicillins by 1 annual dose per 1000 state residents was associated with increases in annual rates of mortality with sepsis of 0.95 (95% CI (0.02,1.88)) per 100,000 persons aged 75-84y, and of 2.97 (0.72,5.22) per 100,000 persons aged 85 + y. Additionally, the percent of individuals aged 50-64y lacking health insurance, as well as the percent of individuals aged 65-84y who are African-American were associated with rates of mortality with sepsis in the corresponding age groups. Our results suggest that prescribing of penicillins is associated with rates of mortality with sepsis in older US adults. Those results, as well as the related epidemiological data suggest that replacement of certain antibiotics, particularly penicillins in the treatment of different syndromes should be considered with the aim of reducing the rates of severe outcomes, including mortality related to bacterial infections.

Sections du résumé

BACKGROUND BACKGROUND
Antibiotic use contributes to the rates of sepsis and the associated mortality, particularly through lack of clearance of resistant infections following antibiotic treatment. At the same time, there is limited information on the effects of prescribing of some antibiotics vs. others on subsequent sepsis and sepsis-related mortality.
METHODS METHODS
We used a multivariable mixed-effects model to relate state-specific rates of outpatient prescribing overall for oral fluoroquinolones, penicillins, macrolides, and cephalosporins between 2014 and 2015 to state-specific rates of mortality with sepsis (ICD-10 codes A40-41 present as either underlying or contributing causes of death on a death certificate) in different age groups of US adults between 2014 and 2015, adjusting for additional covariates and random effects associated with the ten US Health and Human Services (HHS) regions.
RESULTS RESULTS
Increase in the rate of prescribing of oral penicillins by 1 annual dose per 1000 state residents was associated with increases in annual rates of mortality with sepsis of 0.95 (95% CI (0.02,1.88)) per 100,000 persons aged 75-84y, and of 2.97 (0.72,5.22) per 100,000 persons aged 85 + y. Additionally, the percent of individuals aged 50-64y lacking health insurance, as well as the percent of individuals aged 65-84y who are African-American were associated with rates of mortality with sepsis in the corresponding age groups.
CONCLUSIONS CONCLUSIONS
Our results suggest that prescribing of penicillins is associated with rates of mortality with sepsis in older US adults. Those results, as well as the related epidemiological data suggest that replacement of certain antibiotics, particularly penicillins in the treatment of different syndromes should be considered with the aim of reducing the rates of severe outcomes, including mortality related to bacterial infections.

Identifiants

pubmed: 32087679
doi: 10.1186/s12879-020-4901-7
pii: 10.1186/s12879-020-4901-7
pmc: PMC7036250
doi:

Substances chimiques

Anti-Bacterial Agents 0
Penicillins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

169

Subventions

Organisme : NIGMS NIH HHS
ID : U54 GM088558
Pays : United States
Organisme : NIGMS NIH HHS
ID : U54GM088558
Pays : United States

Références

Clin Infect Dis. 2007 Mar 1;44 Suppl 2:S27-72
pubmed: 17278083
Korean J Intern Med. 2014 Jan;29(1):27-30
pubmed: 24574830
J Crit Care. 2016 Feb;31(1):58-62
pubmed: 26601855
Trends Ecol Evol. 1997 Dec;12(12):482-7
pubmed: 21238165
Int J Antimicrob Agents. 2018 Dec;52(6):790-798
pubmed: 30145249
Clin Infect Dis. 2019 Jun 18;69(1):182-188
pubmed: 30462185
J Antimicrob Chemother. 2018 Mar 1;73(suppl_3):iii2-iii78
pubmed: 29514274
BMJ. 2010 May 18;340:c2096
pubmed: 20483949
Respir Med. 2013 Jun;107(6):800-15
pubmed: 23522403
F1000Res. 2018 Jul 23;7:
pubmed: 30079235
Int J Antimicrob Agents. 2019 Jul;54(1):23-34
pubmed: 30851403
Lancet Infect Dis. 2018 Oct;18(10):1138-1149
pubmed: 30126643
BMC Public Health. 2019 Aug 19;19(1):1138
pubmed: 31426780
J Antimicrob Chemother. 2008 Jan;61(1):26-38
pubmed: 17986491
Antimicrob Agents Chemother. 2010 Nov;54(11):4851-63
pubmed: 20733044
JAMA Netw Open. 2019 Feb 1;2(2):e187571
pubmed: 30768188
Clin Infect Dis. 2015 Jan 1;60(1):88-95
pubmed: 25258352
Am J Respir Crit Care Med. 2008 Feb 1;177(3):279-84
pubmed: 17975201
J Antimicrob Chemother. 2013 Nov;68(11):2667-74
pubmed: 23766490
Am J Respir Crit Care Med. 2015 Jun 1;191(11):1216-7
pubmed: 26029831
Am J Med. 2016 Dec;129(12):1331-1333
pubmed: 26924388
J Antimicrob Chemother. 2012 Oct;67(10):2514-22
pubmed: 22761331
Int J Health Geogr. 2010 Feb 15;9:9
pubmed: 20156361
MMWR Morb Mortal Wkly Rep. 2016 Apr 08;65(13):342-5
pubmed: 27054476
J Hosp Med. 2015 Jan;10(1):26-31
pubmed: 25263548
PLoS One. 2014 May 30;9(5):e97714
pubmed: 24878897
Euro Surveill. 2020 Nov;25(45):
pubmed: 33183408
Ann Am Thorac Soc. 2015 Feb;12(2):216-20
pubmed: 25569845
Crit Care. 2014 Nov 21;18(6):596
pubmed: 25412897
J Antimicrob Chemother. 2018 Jun 1;73(6):1700-1707
pubmed: 29394363
Antimicrob Agents Chemother. 2006 Nov;50(11):3646-50
pubmed: 16940064
Antimicrob Agents Chemother. 2016 Apr 22;60(5):3170-3
pubmed: 26926640
J Med Microbiol. 2017 Aug;66(8):1253-1256
pubmed: 28792379
BMC Med. 2018 Aug 23;16(1):137
pubmed: 30134939
Antimicrob Agents Chemother. 2010 May;54(5):2010-6
pubmed: 20211888
J Hosp Infect. 2019 Apr;101(4):426-427
pubmed: 30826342
Antimicrob Agents Chemother. 2017 Apr 24;61(5):
pubmed: 28193660
Medicine (Baltimore). 2016 May;95(20):e3694
pubmed: 27196480
Prev Chronic Dis. 2015 Jan 15;12:E04
pubmed: 25590598
Nat Clim Chang. 2018 Jun;8(6):510-514
pubmed: 30369964
J Am Geriatr Soc. 2012 Jun;60(6):1070-7
pubmed: 22642542
N Engl J Med. 2018 Nov 1;379(18):1732-1744
pubmed: 30380384

Auteurs

Edward Goldstein (E)

Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, 02115, USA. egoldste@hsph.harvard.edu.

Marc Lipsitch (M)

Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, 02115, USA.
Department of Immunology and Infectious Diseases, Harvard TH Chan School of Public Health, Boston, MA, 02115, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH